Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis

…, J Fleisher, J Lampa, P Nowak, JC Vesterbacka… - Jama, 2021 - jamanetwork.com
Importance Clinical trials assessing the efficacy of IL-6 antagonists in patients hospitalized
for COVID-19 have variously reported benefit, no effect, and harm. Objective To estimate the …

Gut microbiota diversity predicts immune status in HIV-1 infection

…, U Neogi, K Holm, JR Hov, K Noyan, J Vesterbacka… - Aids, 2015 - journals.lww.com
Objective: HIV-1 infection is characterized by altered intestinal barrier, gut microbiota dysbiosis,
and systemic inflammation. We hypothesized that changes of the gut microbiota predict …

[HTML][HTML] Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a …

…, CIE Smith, D Wullimann, J Vesterbacka… - …, 2021 - thelancet.com
Background Patients with immunocompromised disorders have mainly been excluded from
clinical trials of vaccination against COVID-19. Thus, the aim of this prospective clinical trial …

[PDF][PDF] Immunodeficiency syndromes differentially impact the functional profile of SARS-CoV-2-specific T cells elicited by mRNA vaccination

…, L Hansson, S Mielke, P Nowak, J Vesterbacka… - Immunity, 2022 - cell.com
Many immunocompromised patients mount suboptimal humoral immunity after SARS-CoV-2
mRNA vaccination. Here, we assessed the single-cell profile of SARS-CoV-2-specific T …

Additive effects of booster mRNA vaccination and SARS-CoV-2 Omicron infection on T cell immunity across immunocompromised states

…, S Mielke, P Nowak, J Vesterbacka… - Science translational …, 2023 - science.org
Suboptimal immunity to SARS-CoV-2 mRNA vaccination has frequently been observed in
individuals with various immunodeficiencies. Given the increased antibody evasion properties …

[HTML][HTML] Metabolic perturbation associated with COVID-19 disease severity and SARS-CoV-2 replication

…, G Ahlén, M Asghar, M Sällberg, J Vesterbacka… - Molecular & Cellular …, 2021 - ASBMB
Viruses hijack host metabolic pathways for their replicative advantage. In this study, using
patient-derived multiomics data and in vitro infection assays, we aimed to understand the role …

[HTML][HTML] Tocilizumab shortens time on mechanical ventilation and length of hospital stay in patients with severe COVID‐19: a retrospective cohort study

J Eimer, J Vesterbacka, AK Svensson… - Journal of internal …, 2021 - ncbi.nlm.nih.gov
Methods We conducted a retrospective cohort study at Karolinska University Hospital
Huddinge between 11 March and 15 April 2020 (regional ethical approval: Drn 2020‐3139). …

Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortium

…, AA Monforte, E Fontas, J Vesterbacka… - The Lancet …, 2021 - thelancet.com
Background Weight gain effects of individual antiretroviral drugs are not fully understood.
We investigated associations between a prespecified clinically significant increase (>7%) in …

[HTML][HTML] Richer gut microbiota with distinct metabolic profile in HIV infected Elite Controllers

J Vesterbacka, J Rivera, K Noyan, M Parera, U Neogi… - Scientific reports, 2017 - nature.com
Gut microbiota dysbiosis features progressive HIV infection and is a potential target for
intervention. Herein, we explored the microbiome of 16 elite controllers (EC), 32 antiretroviral …

[HTML][HTML] MAIT cell compartment characteristics are associated with the immune response magnitude to the BNT162b2 mRNA anti-SARS-CoV-2 vaccine

…, JR Muvva, CIE Smith, J Vesterbacka… - Molecular …, 2022 - Springer
Mucosa-associated invariant T (MAIT) cells are unconventional T cells with innate-like capacity
to rapidly respond to microbial infection via MR1-restricted antigen recognition. Emerging …